CDX-527 was demonstrated to have potent T-cell activation by increasing IL-2 and IFNγ production and anti-tumor activity to CD27-expressing lymphoma cells in an immunodeficient mouse model, with comparable anti-tumor activity to separate CD27 agonizing and PDL1 inhibiting monoclonal antibodies. This evidence concerns the gene IFNG and neoplasm.